(Q34281235)

English

Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group

scientific article published on September 13, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group (English)

1 reference

10.1200/JCO.2010.29.7390

https://api.crossref.org/works/10.1200/JCO.2010.29.7390

12 July 2024

phase II clinical trial

0 references

rhabdomyosarcoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

William H. Meyer

9

object named as

William H Meyer

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

James R. Anderson

8

object named as

James R Anderson

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Douglas S Hawkins

10

object named as

Douglas S Hawkins

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Leo Mascarenhas

1

object named as

Leo Mascarenhas

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837952

12 July 2024

Sarah S. Donaldson

5

object named as

Sarah S. Donaldson

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837952

12 July 2024

7

object named as

David M. Parham

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837952

12 July 2024

author name string

Elizabeth R. Lyden

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837952

12 July 2024

Philip P. Breitfeld

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837952

12 July 2024

David O. Walterhouse

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837952

12 July 2024

Charles N. Paidas

6

0000-0001-9991-9604

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837952

12 July 2024

language of work or name

0 references

publication date

13 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

full work available at URL

https://europepmc.org/articles/pmc2974343?pdf=render

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837952

12 July 2024

http://intl.jco.org/cgi/content/abstract/28/30/4658

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837952

12 July 2024

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20837952/pdf/?tool=EBI

Portable Document Format

online access status

content deliverer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837952

12 July 2024

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20837952/?tool=EBI

online access status

content deliverer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837952

12 July 2024

https://europepmc.org/articles/PMC2974343

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837952

12 July 2024

https://europepmc.org/articles/PMC2974343?pdf=render

Portable Document Format

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837952

12 July 2024

https://doi.org/10.1200/jco.2010.29.7390

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837952

12 July 2024

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2010.29.7390

1 reference

10.1200/JCO.2010.29.7390

https://api.crossref.org/works/10.1200/JCO.2010.29.7390

12 July 2024

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

4658-4663

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

6 July 2018

Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

6 July 2018

A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

6 July 2018

The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

6 July 2018

Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

6 July 2018

Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

6 July 2018

Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

6 July 2018

Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

6 July 2018

A phase I study of irinotecan in pediatric patients: a pediatric oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

6 July 2018

Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

6 July 2018

Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

6 July 2018

Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

6 July 2018

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhi

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

6 July 2018

The Intergroup Rhabdomyosarcoma Study-II.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

6 July 2018

Topoisomerase I inhibitors: topotecan and irenotecan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

6 July 2018

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

6 July 2018

The intergroup rhabdomyosarcoma study.A preliminary report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

6 July 2018

Low-dose protracted irinotecan as a palliative chemotherapy for advanced neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

28 October 2018

Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

28 October 2018

Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

28 October 2018

Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

28 October 2018

Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

28 October 2018

Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

28 October 2018

Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974343

28 October 2018

Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20837952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20837952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognosis of children with soft tissue sarcoma who relapse after achieving a complete response. A report from the Intergroup Rhabdomyosarcoma Study I

1 reference

https://pubmed.ncbi.nlm.nih.gov/20837952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/20837952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20837952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Third Intergroup Rhabdomyosarcoma Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20837952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan for children with relapsed solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20837952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2010.29.7390

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34281235&oldid=2202134341"